Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( <scp>STEER</scp> )
This real-world analysis of a large US claims database shows semaglutide was associated with early and significantly greater reductions in the risk of rMACE-3 and rMACE-5 versus tirzepatide among patients with overweight or obesity and ASCVD but without diabetes.
Authors
- Kerem Özer
- SIGNE STENSEN
- Mayer Bassan
- Bríain ó Hartaigh
- Zhenxiang Zhao
- Victoria Divino
- Lauren Wilson
Institutions
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk (United States) (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1111/dom.70436
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 61.46